Device Trial Radar · NCT05530889
Evaluating Quality of Life Benefits of ACUVUE® Theravision® With Ketotifen in Subjects With Ocular Allergies
Last checked: Nov 20, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 15, 2024
Primary completion
May 13, 2024
Study completion May 13, 2024
Sponsor
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 7, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a prospective, randomized, bilateral eye, crossover, non-masked single site pilot study to compare the severity of symptoms of itching between test and control lens after two weeks of wear.
Conditions
- Ocular Physiology
Interventions
TEST LensDevice
ACUVUE® Theravision® with Ketotifen
CONTROL LensDevice
1-DAY ACUVUE® MOIST.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjective rating of itchinessTime frame: up to 2-week follow-up
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.